Claims

WHAT IS CLAIMED IS:

1. An use of ureidomustine for the manufacture of medicament for the treatment of cancer, wherein said cancer is selected from the group consisting of leukemia, lymphoma, small lung cell carcinoma (SCLC), glioblastoma and sarcoma.

2. The use according to claim 1, wherein said cancer is leukemia.

3. The use according to claim 1, wherein said cancer is lymphoma.

4. The use according to claim 1, wherein said cancer is small lung cell carcinoma.

5. The use according to claim 1, wherein said cancer is sarcoma.

6. The use according to claim 1, wherein said medicament results in a therapeutically significant reduction in the number of said cancer cells and does not result in significant toxicities against non-malignant tissues.

7. The use according to claim 1, wherein said ureidomustine is formulated as a pharmaceutical composition.

8. The use according to claim 1, wherein the medicament further comprise another anti-cancer active agent.